IOTA 3 Ovarian tumour characterisation - Multicentre prospective assessment study on the pre-operative characterisation of ovarian tumours based on predictive computer models
From 01-06-2008 to 31-05-2012
Description
The aim is to prospectively test and implement previously developed mathematical algorithms for the pre-operative classification of adnexal masses. IOTA phase 3 is a prospective multicentre study. The information obtained will be used to define the optimal management of patients presenting with adnexal tumours. More than 2,000 patients, with at least one adnexal mass, will be recruited and studied within 3 months before investigative surgery. Medical and family histories will be recorded. Transvaginal ultrasonography with colour Doppler imaging will be used to derive indices of tumour form and blood flow. A sample of peripheral venous blood will be taken for the analyses of serum CA-125 and other tumour markers and in certain centres additional blood will be taken and stored appropriately to test proteomic pattern analysis. Findings at surgery and the histological classification of excised tissues as malignant or benign (and by cell type) will be used as outcome measures. Conventional and novel algorithms (including proteomic patterns), which can be used to effectively classify difficult adnexal masses will be tested prospectively in centres throughout the world.Dirk Timmerman (spokesperson)
Team
- Bart De Moor, Co-promoter
- Sabine Van Huffel, Co-promoter
- Olivier Gevaert, Team member
- Vanya Van Belle, Team member
- Anneleen Daemen, Team member
Financing
Funding: IWT - Agentschap voor Innovatie door Wetenschap en Technologie
Program/Grant Type: IWT TBM - VLAIO TBM Projects Applied Biomedical Research with a Primary Social finality
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.